Evidence method
Sequential · gp.financial.deposits
8.79% · CORE · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
PBFS · Sep 30, 2025
Pioneer Bancorp, Inc./MD. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001104659-25-108497Bank
Evidence method
Level · gp.fundamentals.cash
$228.6M · CORE · VALID
Evidence method
Sequential · gp.financial.loans
4.61% · CORE · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History30 statesSelf-history eligible
Jun 30, 20213/6 normalizedLevel 3Sep 30, 20213/6 normalizedLevel 3Dec 31, 20213/6 normalizedLevel 3Mar 31, 20225/6 normalizedLevel 3Jun 30, 20226/6 normalizedLevel 3Sep 30, 20226/6 normalizedLevel 3Dec 31, 20226/6 normalizedLevel 3Mar 31, 20236/6 normalizedLevel 3Jun 30, 20236/6 normalizedLevel 3Sep 30, 20236/6 normalizedLevel 3Dec 31, 20236/6 normalizedLevel 3Mar 31, 20246/6 normalizedLevel 3Jun 30, 20246/6 normalizedLevel 3Sep 30, 20246/6 normalizedLevel 3Mar 31, 20253/3 normalizedLevel 3Jun 30, 20253/3 normalizedLevel 3Sep 30, 20253/3 normalizedLevel 3Dec 31, 20253/3 normalizedLevel 3Mar 31, 20265/5 normalizedLevel 3Jun 30, 20265/5 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 1.17%
- Current
- 8.79%
- Delta
- 7.62%
- Previous
- $122.1M
- Current
- $228.6M
- Delta
- $106.5M
- Previous
- 3.74%
- Current
- 4.61%
- Delta
- 0.86%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.